CLN8 (Protein CLN8, Ceroid-Lipofuscinosis, Neuronal 8 (Epilepsy, Progressive with Mental Retardation))

Référence 478195-100ul

Conditionnement : 100ul

Marque : US Biological

Contactez votre distributeur local :


Téléphone : +1 850 650 7790


478195 CLN8 (Protein CLN8, Ceroid-Lipofuscinosis, Neuronal 8 (Epilepsy, Progressive with Mental Retardation))

Clone Type
Polyclonal
Host
rabbit
Source
human
Swiss Prot
Q9UBY8
Isotype
IgG
Grade
Affinity Purified
Applications
WB
Crossreactivity
Hu
Accession #
NP_061764
Gene #
CLN8
Shipping Temp
Blue Ice
Storage Temp
-20°C

CLN8 is a transmembrane protein belonging to a family of proteins containing TLC domains, which are postulated to function in lipid synthesis, transport, or sensing. The protein localizes to the endoplasmic reticulum (ER), and may recycle between the ER and ER-Golgi intermediate compartment. Mutations in this gene are associated with progressive epilepsy with mental retardation (EMPR), which is a subtype of neuronal ceroid lipofuscinoses (NCL). Patients with mutations in this gene have altered levels of sphingolipid and phospholipids in the brain. Childhood-onset NCL are a group of autosomal recessive progressive encephalopathies characterized by the accumulation of autofluorescent material, mainly ATP synthase subunit C, in various tissues, notably in neurons. Based on clinical features, the country of origin of patients, and the molecular genetic background of the disorder, at least seven different forms are thought to exist. CLN8 is characterized by normal early development, onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation.This gene encodes a transmembrane protein belonging to a family of proteins containing TLC domains, which are postulated to function in lipid synthesis, transport, or sensing. The protein localizes to the endoplasmic reticulum (ER), and may recycle between the ER and ER-Golgi intermediate compartment. Mutations in this gene are associated with progressive epilepsy with mental retardation (EMPR), which is a subtype of neuronal ceroid lipofuscinoses (NCL). Patients with mutations in this gene have altered levels of sphingolipid and phospholipids in the brain.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Product Type: Pab|Isotype: IgG|Host: rabbit|Source: human|Concentration: ~0.5mg/ml|Form: Supplied as a liquid in PBS, 2% sucrose, 0.09% sodium azide.|Purity: Purified by affinity chromatography. |Immunogen: Synthetic peptide corresponding to the N-terminal region of human CLN8|Specificity: Recognizes human CLN8. ||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
Synthetic peptide corresponding to the N-terminal region of human CLN8
Form
Supplied as a liquid in PBS, 2% sucrose, 0.09% sodium azide.
Purity
Purified by affinity chromatography.
Specificity
Recognizes human CLN8.